This company listing is no longer active
ECTIN B Stock Overview
A pharmaceutical company, engages in developing a treatment that eliminates cancer tumors. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Ectin Research AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.028 |
| 52 Week High | SEK 1.48 |
| 52 Week Low | SEK 0.0005 |
| Beta | 1.41 |
| 11 Month Change | -79.71% |
| 3 Month Change | -96.00% |
| 1 Year Change | -94.70% |
| 33 Year Change | -99.56% |
| 5 Year Change | n/a |
| Change since IPO | -99.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| ECTIN B | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -58.8% | 0.9% | -0.2% |
| 1Y | -94.7% | 9.3% | 11.8% |
Return vs Industry: ECTIN B underperformed the Swedish Pharmaceuticals industry which returned 86.4% over the past year.
Return vs Market: ECTIN B underperformed the Swedish Market which returned 21% over the past year.
Price Volatility
| ECTIN B volatility | |
|---|---|
| ECTIN B Average Weekly Movement | 253.3% |
| Pharmaceuticals Industry Average Movement | 10.7% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.3% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: ECTIN B's share price has been volatile over the past 3 months.
Volatility Over Time: ECTIN B's weekly volatility has increased from 139% to 253% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 1 | Anna-Carin Sjoblom-Hallen | www.ectinresearch.com |
Ectin Research AB, a pharmaceutical company, engages in developing a treatment that eliminates cancer tumors. Its drug candidate MFA-370 that is in Phase I/II clinical trial for the treatment of metastatic urothelial bladder cancer. The company was incorporated in 2013 and is based in Mölndal, Sweden.
Ectin Research AB Fundamentals Summary
| ECTIN B fundamental statistics | |
|---|---|
| Market cap | SEK 355.33k |
| Earnings (TTM) | -SEK 17.55m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs ECTIN B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ECTIN B income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 17.55m |
| Earnings | -SEK 17.55m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.38 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -986.5% |
How did ECTIN B perform over the long term?
See historical performance and comparison